BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsEarnings

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 3, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026.

Related news

ARWRArrowhead Pharmaceuticals2026-07-21 11:30 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

ETONEton Pharmaceuticals2026-10-29 10:50 EST

Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

ETONEton Pharmaceuticals2026-08-03 10:50 EST

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

AGIOAgios Pharmaceuticals, Inc.2026-10-08 11:00 EST

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

CAPRCapricor Therapeutics2026-11-03 14:00 EST

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

RAREUltragenyx Pharmaceutical2026-10-27 20:05 EST

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-11-07 21:15 EST

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

ARWRArrowhead Pharmaceuticals2026-11-04 12:30 EST

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

ARWRArrowhead Pharmaceuticals2026-11-03 21:00 EST

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

ARWRArrowhead Pharmaceuticals2026-10-27 15:36 EST

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Stock data

Close
57.46 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States